Conjugated Estrogens And Medroxyprogesterone Acetate (Prempro)

Trade Name : Prempro

Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

TABLET, SUGAR COATED

Strength .31.5 mg/1mg/1

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE Estrogen [EPC],Estrogen Receptor Agonists [MoA],Estrogens, Conjugated (USP) [CS],Progesterone Congeners [CS],Progestin [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Conjugated Estrogens And Medroxyprogesterone Acetate (Prempro) which is also known as Prempro and Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. It is available in strength of .3; 1.5 mg/1; mg/1 per ml. Read more

Conjugated Estrogens And Medroxyprogesterone Acetate (Prempro) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Arrayn- Estrogen Plus Progestin Therapy
  • Cardiovascular Disorders and Probable Dementia
  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia .
  • The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo .
  • The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women .
  • Breast Cancer
  • The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer .
  • In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.
  • Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
  • Arrayn- Estrogen-Alone Therapy
  • Endometrial Cancer
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding .
  • Cardiovascular Disorders and Probable Dementia
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia .
  • The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo .
  • The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women .
  • In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.
  • Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
  • WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA
  • See full prescribing information for complete boxed warning.
  • Estrogen Plus Progestin Therapy
  • Estrogen-Alone Therapy
  • PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for:
  • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ()
  • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ()
  • Prevention of Postmenopausal Osteoporosis ()
  • Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
  • PREMPRO: one tablet containing conjugated estrogens (CE) plus medroxyprogesterone acetate (MPA) taken orally once daily. ()n PREMPHASE: one maroon tablet containing 0.625 mg CE taken orally on days 1 through 14, and one light-blue tablet containing 0.625 mg CE plus 5.0 mg MPA taken orally on days 15 through 28. ()
  • PREMPRO Tablets: 0.3 mg CE plus 1.5 mg MPA, 0.45 mg CE plus 1.5 mg MPA, 0.625 mg CE plus 2.5 mg MPA, 0.625 mg CE plus 5 mg MPA.n PREMPHASE Tablets: 0.625 mg CE, 0.625 mg CE plus 5 mg MPA.
  • PREMPRO or PREMPHASE therapy should not be used in women with any of the following conditions:
  • Undiagnosed abnormal genital bleeding ()
  • Known, suspected, or history of breast cancer (, )
  • Known or suspected estrogen-dependent neoplasia (, )
  • Active DVT, PE, or a history of these conditions (, )
  • Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions (, )
  • Known anaphylactic reaction or angioedema to PREMPRO/PREMPHASE (, )
  • Known liver dysfunction or disease (, )
  • Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ()
  • Known or suspected pregnancy (, )
  • No data
  • Estrogens increase the risk of gallbladder disease ()
  • Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs (, , , )
  • Monitor thyroid function in women on thyroid replacement therapy (, )
  • The following serious adverse reactions are discussed elsewhere in the labeling:
  • In two prospective, randomized clinical studies, the most common adverse reactions > 5 percent are abdominal pain, asthenia, back pain, headache, flatulence, nausea, depression, pruritus, breast pain, dysmenorrhea, and leukorrhea. ()n n n
  • Data from a single-dose drug-drug interaction study involving conjugated estrogens and medroxyprogesterone acetate indicate that the pharmacokinetic disposition of both drugs is not altered when the drugs are coadministered. No other clinical drug-drug interaction studies have been conducted with CE plus MPA.
  • In vitro
  • in vivo
  • Hypericum perforatum
  • Aminoglutethimide administered concomitantly with MPA may significantly depress the bioavailability of MPA.
  • Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism ()
  • Aminoglutethimide administered concomitantly with MPA may significantly depress the bioavailability of medroxyprogesterone acetate ()
  • No data
  • Nursing Mothers: Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk ()
  • Geriatric Use: An increased risk of probable dementia in women over 65 years of age was reported in the Women's Health Initiative Memory ancillary studies of the Women's Health Initiative (, )
  • Overdosage of estrogen plus progestin may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of PREMPRO or PREMPHASE therapy with institution of appropriate symptomatic care.
  • Premarin (conjugated estrogens tablets, USP) for oral administration contains a mixture obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains as concomitant components, as sodium sulfate conjugates, 17 u03b1-dihydroequilin, 17 u03b1-estradiol and 17 u03b2-dihydroequilin.
  • Medroxyprogesterone acetate is a derivative of progesterone. It is a white to off-white, odorless, crystalline powder, stable in air, melting between 200u00b0C and 210u00b0C. It is freely soluble in chloroform, soluble in acetone and in dioxane, sparingly soluble in alcohol and in methanol, slightly soluble in ether, and insoluble in water. The chemical name for MPA is pregn-4-ene-3, 20-dione, 17-(acetyloxy)-6-methyl-, (6u03b1)-. Its molecular formula is CHO, with a molecular weight of 386.53. Its structural formula is:
  • PREMPRO 0.3 mg/1.5 mg and 0.45 mg/1.5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, microcrystalline cellulose, carnauba wax, hypromellose, hydroxypropyl cellulose, sucrose, Eudragit NE 30D, lactose monohydrate, magnesium stearate, polyethylene glycol, titanium dioxide, yellow iron oxide, propylene glycol and black iron oxide.
  • PREMPRO 0.625 mg/2.5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, microcrystalline cellulose, carnauba wax, hypromellose, hydroxypropyl cellulose, sucrose, Eudragit NE 30D, lactose monohydrate, magnesium stearate, polyethylene glycol, propylene glycol, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.
  • PREMPRO 0.625 mg/5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&C Blue No. 2, black iron oxide, and propylene glycol.
  • No data
  • Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breasts, uterus, cervix, vagina, testis, and liver.
  • No data
  • No data
  • No data
  • See .
  • LAB-0502-9.0
  • PREMPROn (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)PREMPHASEn (Conjugated Estrogens plus Medroxyprogesterone Acetate Tablets)
  • Read this PATIENT INFORMATION before you start taking PREMPRO or PREMPHASE and read what you get each time you refill your PREMPRO or PREMPHASE prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
  • What is PREMPRO or PREMPHASE?
  • PREMPRO or PREMPHASE are medicines that contain two kinds of hormones, estrogens and a progestin.
  • What is PREMPRO or PREMPHASE used for?
  • PREMPRO or PREMPHASE is used after menopause to:
  • Who should not take PREMPRO or PREMPHASE?
  • Do not take PREMPRO or PREMPHASE if you have had your uterus (womb) removed (hysterectomy).
  • PREMPRO and PREMPHASE contain a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take PREMPRO or PREMPHASE.
  • Do not take PREMPRO or PREMPHASE if you:
  • Tell your healthcare provider
  • How should I take PREMPRO or PREMPHASE?
  • What are the possible side effects of PREMPRO or PREMPHASE?
  • Side effects are grouped by how serious they are and how often they happen when you are treated.
  • Serious, but less common side effects include:
  • Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:
  • Less serious, but common side effects include:
  • These are not all the possible side effects of PREMPRO or PREMPHASE. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects to Pfizer Inc. at 1-800-438-1985 or to FDA at 1-800-FDA-1088.
  • What can I do to lower my chances of getting a serious side effect with PREMPRO or PREMPHASE?
  • General Information about the safe and effective use of PREMPRO and PREMPHASE
  • Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take PREMPRO or PREMPHASE for conditions for which it was not prescribed. Do not give PREMPRO or PREMPHASE to other people, even if they have the same symptoms you have. It may harm them.
  • Keep PREMPRO and PREMPHASE out of the reach of children.
  • This leaflet provides a summary of the most important information about PREMPRO and PREMPHASE. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about PREMPRO and PREMPHASE that is written for health professionals.
  • What are the ingredients in PREMPRO and PREMPHASE?
  • PREMPRO contains the same conjugated estrogens found in Premarin, which are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17u03b1-dihydroequilin, 17u03b1-estradiol and 17u03b2-dihydroequilin. PREMPRO also contains either 1.5, 2.5, or 5 mg of medroxyprogesterone acetate.
  • PREMPRO 0.3 mg/1.5 mg and 0.45 mg/1.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, lactose monohydrate, carnauba wax, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, titanium dioxide, yellow iron oxide, propylene glycol and black iron oxide.
  • PREMPRO 0.625 mg/2.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, carnauba wax, lactose monohydrate, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, propylene glycol, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.
  • PREMPRO 0.625 mg/5 mg tablets also contain calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&C Blue No. 2, black iron oxide, and propylene glycol.
  • PREMPHASE is two separate tablets. One tablet (maroon color) is 0.625 mg of Premarin, which is a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17 u03b1-dihydroequilin, 17 u03b1-estradiol and 17 u03b2-dihydroequilin. The maroon tablet also contains calcium phosphate tribasic, carnauba wax, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, propylene glycol, FD&C Blue No. 2, FD&C Red No. 40. The second tablet (light-blue color) contains 0.625 mg of the same ingredients as the maroon color tablet plus 5 mg of medroxyprogesterone acetate. The light-blue tablet also contains calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&C Blue No. 2, black iron oxide, and propylene glycol.
  • PREMPRO therapy consists of a single tablet to be taken once daily.
  • PREMPRO 0.3 mg/1.5 mg
  • Blister Card - Each carton includes 1 blister card containing 28 oval, cream tablets. Each tablet contains 0.3 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.
  • PREMPRO 0.45 mg/1.5 mg
  • Blister Card - Each carton includes 1 blister card containing 28 oval, gold tablets. Each tablet contains 0.45 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.
  • PREMPRO 0.625 mg/2.5 mg
  • Blister Card - Each carton includes 1 blister card containing 28 oval, peach tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 2.5 mg of medroxyprogesterone acetate for oral administration.
  • PREMPRO 0.625 mg/5 mg
  • Blister Card - Each carton includes 1 blister card containing 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.
  • PREMPHASE therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28.
  • Each carton includes 1 blister pack containing 28 tablets. One blister pack contains 14 oval, maroon Premarin tablets containing 0.625 mg of conjugated estrogens and 14 oval, light-blue tablets that contain 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.
  • The appearance of PREMPRO tablets is a trademark of Pfizer Inc.
  • The appearance of PREMARIN tablets is a trademark of Pfizer Inc. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F) [see USP Controlled Room Temperature].
  • LAB-0504-9.0Revised May 2019
  • START HERE Rx only NDC 0046-2575-12
  • DAY 1 u2192 DAY 2 u2192 DAY 3 u2192 DAY 4 u2192 DAY 5 u2192 DAY 6 u2192 DAY 7
  • 14 maroon tablets of 0.625 mg conjugated estrogens
  • DAY 14 u2190 DAY 13 u2190 DAY 12 u2190 DAY 11 u2190 DAY 10 u2190 DAY 9 u2190 DAY 8
  • PREMPHASE (conjugated estrogens/medroxyprogesterone acetate tablets)
  • DAY 15 u2192 DAY 16 u2192 DAY 17 u2192 DAY 18 u2192 DAY 19 u2192 DAY 20 u2192 DAY 21
  • 14 light-blue tablets of 0.625 mg conjugated estrogens/5 mg medroxyprogesterone acetate
  • DAY 28 u2190 DAY 27 u2190 DAY 26 u2190 DAY 25 u2190 DAY 24 u2190 DAY 23 u2190 DAY 22
  • NDC 0046-2575-12
  • Pfizer
  • PREMPHASEn (conjugated estrogens/medroxyprogesterone acetate tablets)
  • 14 maroon tablets of 0.625 mg conjugated estrogens
  • 14 light-blue tablets of 0.625 mg conjugated estrogens/ 5 mg medroxyprogesterone acetate
  • Package contains 1 blister card of 28 tablets
  • Rx only
  • 28 Tablets NDC 0046-1105-11
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • Pfizer
  • PREMPROn (conjugated estrogens/medroxyprogesterone acetate tablets)
  • 0.3 mg / 1.5 mg
  • Each cream tablet contains 0.3 mg of Premarin brand of conjugated estrogens and 1.5 mg of medroxyprogesterone acetate.
  • Directions for Use: Take one tablet each day until all tablets have been taken. See accompanying information.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F). [See USP Controlled Room Temperature]
  • Note: Package not child resistant. Keep this and all medications out of the reach of children.
  • PREMPRO 0.3 mg/1.5 mg
  • Distributed by Wyeth Pharmaceuticals LLC A subsidiary of Pfizer Inc Philadelphia, PA 19101
  • www.PREMPRO.com
  • Rx only
  • PAA118009
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • LOT XXXXXXX EXP YYYY MMM
  • NDC 0046-1105-11
  • Pfizer
  • PREMPROn (conjugated estrogens/ medroxyprogesterone acetate tablets)
  • 0.3 mg / 1.5 mg
  • Package contains 1 blister card of 28 tablets.
  • www.PREMPRO.com Rx only
  • 28 Tablets NDC 0046-1106-11
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • Pfizer
  • PREMPROn (conjugated estrogens/medroxyprogesterone acetate tablets)
  • 0.45 mg / 1.5 mg
  • Each gold tablet contains 0.45 mg of Premarin brand of conjugated estrogens and 1.5 mg of medroxyprogesterone acetate.
  • Directions for Use: Take one tablet each day until all tablets have been taken. See accompanying information.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F). [See USP Controlled Room Temperature]
  • Note: Package not child resistant. Keep this and all medications out of the reach of children.
  • PREMPRO 0.45 mg/1.5 mg
  • Distributed by Wyeth Pharmaceuticals LLC A subsidiary of Pfizer Inc Philadelphia, PA 19101
  • www.PREMPRO.com
  • Rx only
  • PAA118010
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • LOT XXXXXXX EXP YYYY MMM
  • NDC 0046-1106-11
  • Pfizer
  • PREMPROn (conjugated estrogens/ medroxyprogesterone acetate tablets)
  • 0.45 mg / 1.5 mg
  • Package contains 1 blister card of 28 tablets.
  • www.PREMPRO.com Rx only
  • 28 Tablets NDC 0046-1107-11
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • Pfizer
  • PREMPROn (conjugated estrogens/medroxyprogesterone acetate tablets)
  • 0.625 mg / 2.5 mg
  • Each peach tablet contains 0.625 mg of Premarin brand of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate.
  • Directions for Use: Take one tablet each day until all tablets have been taken. See accompanying information.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F). [See USP Controlled Room Temperature]
  • Note: Package not child resistant. Keep this and all medications out of the reach of children.
  • MADE IN IRELAND
  • PREMPRO 0.625 mg/2.5 mg
  • Distributed by Wyeth Pharmaceuticals LLC A subsidiary of Pfizer Inc Philadelphia, PA 19101
  • Rx only
  • www.PREMPRO.com
  • PAA118021
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • LOT XXXXXXX EXP YYYY MMM
  • NDC 0046-1107-11
  • Pfizer PREMPROn (conjugated estrogens/ medroxyprogesterone acetate tablets)
  • 0.625 mg / 2.5 mg
  • Rx onlyt
  • Package contains 1 blister card of 28 tablets. www.PREMPRO.com
  • 28 Tablets NDC 0046-1108-11
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • Pfizer
  • PREMPROn (conjugated estrogens/medroxyprogesterone acetate tablets)
  • Rx only
  • 0.625 mg / 5 mg
  • Each light-blue tablet contains 0.625 mg of Premarin brand of conjugated estrogens and 5 mg of medroxyprogesterone acetate.
  • Directions for Use: Take one tablet each day until all tablets have been taken. See accompanying information.
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F). [See USP Controlled Room Temperature]
  • Note: Package not child resistant. Keep this and all medications out of the reach of children.
  • MADE IN IRELAND
  • PREMPRO 0.625 mg/5 mg
  • Distributed by Wyeth Pharmaceuticals LLC A subsidiary of Pfizer Inc Philadelphia, PA 19101
  • www.PREMPRO.com
  • PAA118022
  • WEEK 1 WEEK 2 WEEK 3 WEEK 4
  • LOT XXXXXXX EXP YYYY MMM
  • NDC 0046-1108-11
  • Rx only
  • Pfizer PREMPROn (conjugated estrogens/ medroxyprogesterone acetate tablets)
  • 0.625 mg / 5 mg
  • Package contains 1 blister card of 28 tablets.www.PREMPRO.com

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.